Patents by Inventor Elia Duh

Elia Duh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES
    Publication number: 20230346777
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of ophthalmologic diseases, including non-proliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), retinal ganglion cell/photoreceptor neurodegeneration and cataract.
    Type: Application
    Filed: April 14, 2023
    Publication date: November 2, 2023
    Inventors: William Ernst SCHUBERT, Khaled NASSAR, Peter SANDNER, Carsten TERJUNG, Elia DUH, Hongkwan CHO, Zhenhua XU, Lijuan WU, Lingli ZHOU
  • USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES
    Publication number: 20220241273
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of ophthalmologic diseases, including non-proliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), retinal ganglion cell/photoreceptor neurodegeneration and cataract.
    Type: Application
    Filed: February 8, 2022
    Publication date: August 4, 2022
    Inventors: William Ernst SCHUBERT, Khaled NASSAR, Peter SANDNER, Carsten TERJUNG, Elia DUH, Hongkwan CHO, Zhenhua XU, Lijuan WU, Lingli ZHOU
  • GLP-1R AGONIST AND METHODS OF TREATMENT
    Publication number: 20210353710
    Abstract: In one aspect, GLP-1r agonists including long-acting PEGylated exenatide (NLY01), exenatide, liraglutide, exenatide LAR (long acting), taspoglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, LY2189265 are used to treat ocular ischemic, inflammatory, angiogenic, and/or degenerative conditions.
    Type: Application
    Filed: March 5, 2021
    Publication date: November 18, 2021
    Inventors: Elia Duh, Zhenhua Xu, Lingli Zhou, Seulki Lee, Yumin Oh